Abstract
In the United States, almost 70% of the 23,000 women diagnosed annually with epithelial ovarian cancer present with advanced disease (FIGO stages III-IV). Primary therapy for these patients includes surgical cytoreduction and 6 - 8 courses of platinum- and taxane-based chemotherapy. Although 90% of patients will respond to this multi-modality combination regimen, most patients will experience recurrences. The 5 year survival for women with stage III disease is 15 - 30% and 0 - 20% for those with stage IV disease. Medical and gynecological oncologists, therefore, must be prepared to treat many women with recurrent ovarian cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 1299-1306 |
Number of pages | 8 |
Journal | Expert opinion on pharmacotherapy |
Volume | 2 |
Issue number | 8 |
DOIs | |
State | Published - Aug 27 2001 |
Externally published | Yes |
Keywords
- 5-Fluorouracil
- Carboplatin
- Cisplatin
- Cyclosporin A
- Docetaxel
- Doxorubicin
- Etoposide
- Gemcitabine
- High-dose chemotherapy
- Hormones
- Ifosfamide
- Intraperitoneal chemotherapy
- Liposomal doxorubicin
- Ovarian cancer
- Ovarian neoplasia
- Oxaliplatin
- Paclitaxel
- Platinum-resistant
- Tamoxifen
- Taxanes
- Treatment
- Virorelbine
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)